ライフサイエンスコーパス: IGF receptor

1 significant numbers of cells expressing the IGF receptor.

2 mediated through interaction with the type 1 IGF receptor.

3 nity similar to that of IGF-I for the type I IGF receptor.

4 n NIH 3T3 cells over-expressing human type-I IGF receptor.

5 , which control their access to cell-surface IGF receptors.

6 hich allows IGF-I to better equilibrate with IGF receptors.

7 n experiments revealed galectin-3 binding to IGF-receptor 1 (R1), thus suggesting that interaction of

8 s to IGF-2 (18% cell death), antibody to the IGF receptor (45% cell death), and IGF-1 antisense oligo

9 ve studied the mechanism by which endogenous IGF receptors activate the ERK1/2 mitogen-activated prot

10 availability and, hence, local regulation of IGF receptor activation.

11 yperglycemia is not because of altered IGF-1/IGF receptor activation.

12 I exhibits 2-fold increased affinity for the IGF receptor and augmented post-receptor signaling.

13 ls resulted in enhanced activation of type I IGF receptor and IRS adaptor proteins.

14 is rapidly internalized after binding to the IGF receptor and is rapidly catabolized with release of

15 fibroblasts also accumulate acidic vesicles, IGF receptor and transferrin, indicating that dysferlin

16 on is mediated by high affinity cell surface IGF receptors and modulated by a family of secreted IGF

17 RS), insulin and insulin-like growth factor (IGF) receptors and polypeptides, Notch, Jagged, and HES

18 nd IGF-2, an antibody that blocks the type 1 IGF receptor, and antisense oligonucleotides to inhibit

19 he actions of IGF-I at a point distal to the IGF receptor, and this was not due to IL-1beta-induced c

20 GFs from degradation, limit their binding to IGF receptors, and modulate IGF actions.

21 apoptosis, suggesting that neither IGFs nor IGF receptors are required for this action.

22 ion system inhibited DNA synthesis in an IGF-IGF receptor axis-independent fashion and resulted in th

23 t cancer cell growth, independent of the IGF-IGF receptor axis.

24 anti-IGF-II, anti-insulin receptor, or anti-IGF receptor blocking antibodies caused a significant de

25 t monkeys in the presence and absence of the IGF receptor blocking antibody and ceramide to induce ce

26 A secreted dominant-negative type I IGF receptor (DN-IGFR) had the opposite effect.

27 ossesses two functional copies of the Type-1 IGF receptor gene (igf1ra, igf1rb).

28 2 gene, or conditional disruption of the two IGF receptor genes Igf1r and Insr together in the myocar

29 The insulin/IGF receptor homolog DAF-2 regulates the aging in C. ele

30 mRNA levels for IGF-II, IGF receptor-I, GRP receptor, and EGF receptor in tumors

31 ndent tyrosine phosphorylation of the type I IGF receptor (IGF-IR) and extracellular signal-regulated

32 rated that SHPS-1 was a substrate for type I IGF receptor (IGF-IR) and that IRS-1 competitively inhib

33 ast cancer cells to inhibitors of the type I IGF receptor (IGF-IR) in a manner reversed by the reacti

34 (IGF-I) to induce phosphorylation of type I IGF receptor (IGF-IR), insulin receptor substrate 1, pho

35 ced SH-SY5Y growth is mediated by the type I IGF receptor (IGF-IR).

36 1, including enhanced phosphorylation of the IGF receptor (IGF-R) and insulin receptor substrate as w

37 cer cell lines through action via the type I IGF receptor (IGF-R).

38 cDNAs were more similar to the human type I IGF receptor (IGF-R).

39 The insulin-like growth factor (IGF) receptor (IGF-IR) is necessary for IGF signalling a

40 ts of the malignant phenotype via the type I IGF receptor (IGF1R) and insulin receptor (IR).

41 Insulin receptor (IR) and the type I IGF receptor (IGF1R) are structurally and functionally r

42 ment to evaluate the potential of the type 1 IGF receptor (Igf1r) for targeted anticancer therapy in

43 (IGF-I and IGF-II) and their cognate type 1 IGF receptor (IGF1R) have demonstrated that this signali

44 lonal antibodies directed against the type I IGF receptor (IGF1R) in combination with estrogen recept

45 iferation, motility, and survival.The type I IGF receptor (IGF1R) mediates the effects of IGF-I.

46 Expression of type-1 IGF receptor (IGF1R) mRNA, encoding the cognate receptor

47 fectively antagonizes PAPP-A-mediated type 1 IGF receptor (IGF1R) phosphorylation.

48 king GPC3 and also IGF2, IGF1, or the type 1 IGF receptor (IGF1R) provided conclusive genetic evidenc

49 ific conditional mutagenesis ablating type 1 IGF receptor (IGF1R) signaling.

50 s by disrupting the gene encoding the type 1 IGF receptor (IGF1R) specifically in the mouse brain by

51 hile IGF signaling is mediated by the type 1 IGF receptor (IGF1R), the type 2 receptor (IGF2R/CI-MPR)

52 use osteoblasts the gene encoding the type 1 IGF receptor (Igf1r).

53 le of the type I insulin-like growth factor (IGF) receptor (IGF1R) in cancer metastasis we inhibited

54 oding the type 1 insulin-like growth factor (IGF) receptor (IGF1R).

55 for both IGF-I and IGF-II, as well as type-2 IGF receptor (IGF2R) mRNA was not found to be altered du

56 GF-II-binding function and is termed type II IGF receptor (IGF2R).

57 In this study, we examined the role of the IGF receptor (IGFR) and the importance of IGFR glycosyla

58 ty to the type 1 insulin-like growth factor (IGF) receptor (IGFR).

59 hat neutralization of IGF action by a type I IGF receptor (IGFR1) blocking antibody or neutralization

60 signaling pathways downstream of the type I IGF receptor in a subset of malignant pleural mesothelio

61 lts in dose-dependent phosphorylation of the IGF receptor in the range of 1 to 100 nM.

62 lower amount of IGF that is able to bind to IGF receptors in the arthritic joint.

63 itated the autophosphorylation of the type 1 IGF receptor, increased class IA phosphatidylinositol 3'

64 that this action is mediated through an IGF.IGF receptor-independent pathway.

65 Importantly, the IGF receptor inhibitor NVP-AEW541 and the neutralization

66 Insulin-IGF receptor (InR) signaling has a conserved role in reg

67 daf-2, an insulin/insulinlike growth factor (IGF) receptor (INR) homolog gene, were profoundly Hyp.

68 amed kermit 2 (also recently described as an IGF receptor interacting protein and named XGIPC).

69 results demonstrate that IGF-1 activates the IGF receptor/IRS/PI3K/PKB pathway, and that PI3Kalpha is

70 Phosphorylation of the IGF receptor is rapid and sustained, with maximal phosph

71 .3-3.9 nM) and no biological activity at the IGF receptors (Ki = >10,000 nM) increased the levels of

72 To determine which IGF receptors mediate this effect, we tested seven insul

73 pathway independent of either p53 or the IGF.IGF receptor-mediated cell survival pathway and that IGF

74 r (IGFR) and is essential for activating the IGF receptor-mediated intracellular signalling pathway.

75 Type-2 IGF receptor mRNA expression was reduced to background l

76 ected insulin, IGF-II, insulin receptor, and IGF receptor mRNAs in both the neural tube and the somit

77 daf-2 insulin/IGF receptor mutants have a constitutive-L1-arrest pheno

78 In addition, in an IGF receptor-negative mouse fibroblast cell line, treatm

79 bound IGFBP-3 allows IGF-I release to type I IGF receptors of stromal cells migrating into the fibrin

80 e growth factor (IGF) pathway and the type I IGF receptor on Purkinje cells.

81 actors (IGF) 1 and 2, which activate insulin/IGF receptors on pancreatic cancer cells.

82 of the patients expressed activated insulin/IGF receptors on tumor cells, and this positively correl

83 of insulin-like signaling via DAF-2 insulin/IGF receptor or its intramuscular effector PtdIns-3-kina

84 rent from those resulting from deficiency of Igf receptor or ligand in zebrafish, suggesting a functi

85 Age-related changes in IGF receptors or, more likely, age-related alterations i

86 id not change the expression levels of IGFs, IGF receptors, or other IGFBPs.

87 e to nutrition, and we show that the insulin/IGF receptor pathway is necessary for neuroblasts to exi

88 el with the glp-1 (Notch) and daf-2 (insulin-IGF receptor) pathways, and does not share the same gene

89 ing the survival effect of IGF-I we examined IGF receptor phosphorylation and Akt phosphorylation and

90 IGF-1 secretion and IGF receptor phosphorylation by autocrine IGF-1 occur eq

91 The IGF pathway, acting through the type 1 IGF-receptor, repressed apoptosis of lung fibroblasts bu

92 of DOG1 in GIST involving modulation of IGF/IGF receptor signaling in the tumor microenvironment thr

93 at STC2 efficiently inhibits PAPP-A-mediated IGF receptor signaling in vitro and that transgenic mice

94 rease IGF bioavailability, thereby enhancing IGF receptor signaling.

95 This translocation is a type 1 IGF receptor-signaling independent event as IGFBP-3 indu

96 cluding Irs1 and Irs2, integrate insulin and IGF receptor signals with heterologous pathways to coord

97 ibody (alphaIR3) directed against the type 1 IGF receptor significantly attenuated the ability of IGF

98 ncer cells by a mechanism that relies on the IGF receptor substrate-1 (IRS-1).

99 f2r gene on chromsome 17 encoding the type 2 IGF receptor that is involved in degradation of excess I

100 ect of antisense insulin-like growth factor (IGF) receptor transcripts on the proliferation and tumor

101 factor in several tumor types by binding to IGF receptor type 1 (IGF-1R) and/or the insulin receptor

102 .05) decrease in insulin-like growth factor (IGF) receptor type I beta and an approximately 13-fold (

103 Cell death from inhibition of the type 1 IGF receptor was associated with an increase in caspase

104 were those from young adult monkeys when the IGF receptor was blocked and cell death was further stim

105 afficking of the insulin-like growth factor (IGF) receptor, where the receptor is shuttled to LAMP2-p